Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
about
The Role of Chemokines in Promoting Colorectal Cancer Invasion/MetastasisOvercoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune DysfunctionAnti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic ApproachesExploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer ImmunotherapyTherapeutic potential of chemokine signal inhibition for metastatic breast cancerThe programmed death-1 immune-suppressive pathway: barrier to antitumor immunityAdoptive cell therapy for sarcomaImmune escape mechanisms as a guide for cancer immunotherapyLive imaging and gene expression analysis in zebrafish identifies a link between neutrophils and epithelial to mesenchymal transitionCombination Approaches with Immune-Checkpoint Blockade in Cancer TherapyRecent advances in understanding antitumor immunityImmune checkpoint and inflammation as therapeutic targets in pancreatic carcinomaPhenotype, development, and biological function of myeloid-derived suppressor cellsGenetically engineered mouse models in oncology research and cancer medicineImmunosuppression associated with chronic inflammation in the tumor microenvironmentCooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma ModelsRhabdomyosarcoma: current challenges and their implications for developing therapies.Big opportunities for small molecules in immuno-oncology.Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.Molecular pathways: myeloid complicity in cancer.Isolation of myeloid-derived suppressor cells subsets from spleens of orthotopic liver cancer-bearing mice by fluorescent-activated and magnetic-activated cell sorting: similarities and differences.Classification of current anticancer immunotherapiesIL-12 promotes myeloid-derived suppressor cell recruitment and bacterial persistence during Staphylococcus aureus orthopedic implant infectionMethylcholanthrene-Induced Sarcomas Develop Independently from NOX2-Derived ROS.Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral MacrophagesTLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity.Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.The Role of Prostaglandin E(2) in Tumor-Associated Immunosuppression.Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche.Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management.Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesisPancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer.
P2860
Q26748194-1BE84951-01DC-4B55-B907-63A41A2E7A9BQ26749333-0B5998A3-84E8-409F-B2F9-8B481D73DBE8Q26774312-BCB782D0-8D6C-431F-A4FB-8E6AC9505FEEQ26779184-1C2548AB-5711-4A21-A151-05CEB4620C75Q26798116-A5C7D412-92C8-4011-8CE7-A1435D5F805DQ26829847-BD2A694E-8ED1-4BEF-81DA-A7B3AE6A4EEDQ27009541-2C01FD2C-E8D3-4D28-BB62-9B0929EC33F2Q27024502-BFED3986-AB5E-40DD-86FE-611C0999637FQ27330504-5D76E197-D66C-4063-BE6C-7AAB676937ACQ28066199-250AFF6D-F2CF-4A35-A48E-D09C9A036EEBQ28067217-6371B24C-0AE4-4D15-A250-36ADEB111CBAQ28069864-7CD5331C-59A0-44A0-8A0B-541566E03846Q28079046-0BD3B636-4752-48B5-8AEB-1F7790A0725FQ28079323-E5E50372-5B71-48F4-9AA7-B8E6121B4F41Q28083450-E7A92770-3D5B-43D4-98B7-68B39ACFFBC4Q33725706-0AF9BB17-AE6E-442C-9568-82765E8A5CA3Q34400242-7AEE9083-40AA-437C-961A-F2C209D7E2CFQ34487689-4A807A04-17FE-4C22-8E42-8441C86F92E1Q34552791-89DC2141-482A-44ED-9E7D-3A64F182205DQ34725969-B3A77970-76E5-493C-B114-E8AA56743325Q34732885-78654F93-1D0E-4332-A113-5C46D67D8D4FQ35149637-D2026C0D-110F-44C5-BDAA-105F0086097BQ35328929-9C704843-8E0B-46AB-81B7-B7021EBAA536Q35663908-435816EF-89D0-4660-A1A3-E02786B64B95Q35772377-D1456EA2-E2B6-4174-9614-583540105020Q35958114-22115D0A-C022-4C96-ABD7-51D968D7B0BCQ36041701-D874BB0B-BDAA-4252-BFD1-240AA106C30CQ36304952-DF3D1350-0DA3-40A3-9801-7F74D827F03DQ36390700-7D601495-A5B1-4656-9884-6303231BBBB7Q36561681-8D81666B-B929-4A36-A54B-A84F3EA138E2Q36604012-87C71E32-B2AE-4B2C-B44F-C5CE0DA947ECQ36693101-98D379EB-7E8E-46EC-BB4A-4DAEE05EE650Q36710927-45A20A45-BCB1-41A6-9D23-8EFE5BC4D50EQ36918248-AD205FB2-CA96-417D-9003-58CFB86B4779Q37017190-AE9CB0F1-2A67-47E3-B090-1C7579B3B5FAQ37072889-8C7C6869-8E70-4935-85FF-FFD8D450C841Q37134990-7733B5B0-8889-4B2E-B22A-C1931B4FF447Q37265479-13E4E35D-2A46-42A6-BAA5-23986898101FQ37507187-F53CCAEC-7B33-4A48-B2B6-957DB801574CQ37588378-44DD2296-44AA-4468-8ADF-6E8AA60784FE
P2860
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
@en
type
label
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
@en
prefLabel
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
@en
P2093
P2860
P1476
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy
@en
P2093
Crystal L Mackall
Elizabeth Morse
Jillian P Smith
Rosandra N Kaplan
Steven L Highfill
Yongzhi Cui
P2860
P304
P356
10.1126/SCITRANSLMED.3007974
P407
P50
P577
2014-05-01T00:00:00Z